Revance The (RVNC)

Stock Card

$3.65

$0.00 (0.00%)

As on 06-Feb-2025 16:00EDT

Market cap

$381 Mln

Revenue (TTM)

$247 Mln

P/E Ratio

P/B Ratio

12.3

Div. Yield

0 %

Revance The (RVNC) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-21 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

-2.3
Debt to Equity

-2.6
Book Value

$--
EPS

$-1.9
Face value

--
Shares outstanding

104,390,000

10 Years Aggregate

CFO

$-1,286.48 Mln

EBITDA

$-1,591.51 Mln

Net Profit

$-1,894.36 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Revance The (RVNC)	20.1	18.1	-37.5	-28.4	-35.1	-32.0	-14.0
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 06-Feb-2025 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Revance The (RVNC)	-65.1	-52.4	13.1	-42.4	74.6	-19.4	-43.5
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Revance The (RVNC)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug... candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. As of February 6, 2025, Revance Therapeutics, Inc. operates as a subsidiary of Crown Laboratories, Inc. Read more

CEO & Director

Mr. Mark J. Foley
CEO & Director

Mr. Mark J. Foley
Headquarters

Nashville, TN
Website

https://www.revance.com

FAQs for Revance The (RVNC)

What is the current share price of Revance The (RVNC) Today?

The share price of Revance The (RVNC) is $3.65 (NASDAQ) as of 06-Feb-2025 16:00 EDT. Revance The (RVNC) has given a return of -35.11% in the last 3 years.

What is the current PB & PE ratio of Revance The (RVNC)?

Since, TTM earnings of Revance The (RVNC) is negative, P/E ratio is not available.
The P/B ratio of Revance The (RVNC) is 12.30 times as on 06-Feb-2025, a 59 premium to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.